An update of teriflunomide for treatment of multiple sclerosis

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 177-190

  Oh, Jiwon ^a,b   O'Connor, Paul W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Clinical trials; Multiple sclerosis; Review; Teriflunomide

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CHLOROQUINE; CYCLOSPORIN A; DANAZOL; DIHYDROOROTATE DEHYDROGENASE; GLATIRAMER; INFLUENZA VACCINE; INTERFERON BETA SERINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; TERIFLUNOMIDE;

ADD ON THERAPY; ADJUVANT THERAPY; ALOPECIA; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BACKACHE; BRAIN ATROPHY; CYTOPENIA; DIARRHEA; DNA SYNTHESIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HAIR LOSS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIMB PAIN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PARESTHESIA; PERIPHERAL NEUROPATHY; PILOT STUDY; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN AGGREGATION; RELAPSE; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; RNA SYNTHESIS; SIDE EFFECT; STEADY STATE; T LYMPHOCYTE ACTIVATION; TRIGEMINUS NEURALGIA;

EID: 84877888607     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S30947     Document Type: Review

References (59)

1. Marriott JJ, O'Connor PW. Emerging therapies in relapsing-remitting multiple sclerosis. Rev Recent Clin Trials. 2010;5:179-188.
2. Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2003;1:CD002047.
3. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity - I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol. 1985;7:7-18.
4. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004;76:950-960.
5. Posevitz V. Teriflunomide selectively suppresses antigen induced T cell expansion in a TCR avidity dependent fashion. Paper presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
6. Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J. 1998;336:299-303.
7. Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995;275:1043-1049.
8. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93: 198-208.
9. Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. 1998;273:21682-21691.
10. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000;47:273-289.
11. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem. 1995;270:29682-29689.
12. Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Chong AS. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol. 1997;159:22-27.
13. Korn T, Toyka K, Hartung HP, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain. 2001;124:1791-1802.
14. Siemasko K, Chong AS, Jack HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol. 1998;160:1581-1588.
15. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem. 1995;270:12398-12403.
16. Hoskin DW, Taylor RM, Makrigiannis AP, James H, Lee TD. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction. Int J Immunopharmacol. 1998;20:505-513.
17. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 1999;162:2095-2102.
18. González-Alvaro I, Ortiz AM, Domínguez-Jiménez C, Aragón-Bodi A, Díaz Sánchez B, Sánchez-Madrid F. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis. 2009;68:1644-1650.
19. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 1993;334:161-164.
20. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol. 2000;165:5962-5969.
21. Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol. 1999;127:1589-1596.
22. Jankovic V, Samardzic T, Stosic-Grujicic S, Popadic D, Trajkovic V. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide. Cell Immunol. 2000;199:73-80.
23. Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005;52:2730-2739.
24. Layseca-Espinosa E, Pedraza-Alva G, Montiel JL, et al. T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J Leukoc Biol. 2003;74:1083-1093.
25. Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol. 2002;169:3392-3399.
26. Deage V, Burger D, Dayer JM. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissueinhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases. Eur Cytokine Netw. 1998;9:663-668.
27. Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villaggio B. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheumatic Dis. 2003;62:297-302.
28. Kraan MC, de Koster BM, Elferink JG, Post WJ, Breedveld FC, Tak PP. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum. 2000;43:1488-1495.
29. Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 2000;43:1820-1830.
30. Fuentealba RA, Marasa J, Diamond MI, Piwnica-Worms D, Weihl CC. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet. 2012;21:664-680.
31. Sanofi. Teriflunomide data on file. Paris, France: Sanofi; 2012.
32. Limsakun T, Menguy-Vacheron F, Mazarin C. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. Programs and abstracts of the 62nd American Academy of Neurology Annual Meeting; April 10-17, 2010; Toronto, ON, Canada.
33. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. Int MS J. 2008;15:62-68.
34. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998;8:681-694.
35. Weissert R, Wallström E, Storch MK, et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest. 1998;102: 1265-1273.
36. Korn T, Mitsdoerffer M, Kuchroo VK. Immunological basis for the development of tissue inflammation and organ-specific autoimmunity in animal models of multiple sclerosis. Results Probl Cell Differ. 2010;51: 43-74.
37. Merrill JE, Hanak S, Pu SF, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol. 2009;256:89-103.
38. Styren S, Barbier A, Selk D, Wettstein JG. Beneficial effects of teriflunomide in experimental allergic encephalomyelitis. Paper presented at Society for Neuroscience Annual Meeting; October 23-27, 2004; San Diego, CA, USA.
39. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900.
40. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18:1278-1289.
41. Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012;78:1877-1885.
42. Freedman MS, WJ, Frangin GA, et al. Oral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. Programs and abstracts of the 62nd American Academy of Neurology Annual Meeting; April 10-17, 2010; Toronto, ON, Canada.
43. Sanofi. Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with interferon-beta (TERACLES). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01252355?term=teriflunomide&ra nk=3. Accessed October 30, 2012.
44. Sanofi. Long term safety of teriflunomide when added to interferon-beta or glatiramer acetate in patients with multiple sclerosis. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00811395?term=teriflunomide&ra nk=4. Accessed October 30, 2012.
45. Bar-Or A, Freedman MS, Kremenchutzky F, et al. Effect of teriflunomide on immune responses to seasonal influenza vaccination in patients with relapsing multiple sclerosis: results from the TERIVA study. Paper presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
46. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365: 1293-1303.
47. Sanofi. Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00803049?ter m=teriflunomide&rank=13. Accessed October 30, 2012.
48. Kappos L, Comi G, Confavreux C, et al. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study. Paper presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
49. Vermersch P, Czlonkowska A, Grimaldi LME, et al. A multicenter, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Paper presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
50. Sanof i. Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC). 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00622700?term=TOPIC&rank=1. Accessed October 30, 2012.
51. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001;63:106-112.
52. Fukushima R, Kanamori S, Hirashiba M, et al. Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol. 2007;24:310-316.
53. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62:1494-1503.
54. Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64:2085-2094.
55. Kieseier B, Benamor M, Benzerdjeb H, Stüve O. Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. Paper presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
56. White DH, Lynskey NV, Jones PB. Leflunomide use in New Zealand. A national prospective post-marketing study. Intern Medicine J. 2009;39: 95-102.
57. Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheumatic Dis. 2003;62:50-57.
58. Rahmlow M, Shuster EA, Dominik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol. 2008;65: 1538-1539.
59. Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124:75-84.